ZA957938B - Estramustine formulations with improved pharmaceutical properties - Google Patents

Estramustine formulations with improved pharmaceutical properties

Info

Publication number
ZA957938B
ZA957938B ZA957938A ZA957938A ZA957938B ZA 957938 B ZA957938 B ZA 957938B ZA 957938 A ZA957938 A ZA 957938A ZA 957938 A ZA957938 A ZA 957938A ZA 957938 B ZA957938 B ZA 957938B
Authority
ZA
South Africa
Prior art keywords
estramustine
pct
date
formulations
pharmaceutical properties
Prior art date
Application number
ZA957938A
Other languages
English (en)
Inventor
Alessandro Martini
Giuseppe Maccari
Lorena Muggetti
Giuseppe Colombo
Giovanni Buzzi
Original Assignee
Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Ab filed Critical Pharmacia Ab
Publication of ZA957938B publication Critical patent/ZA957938B/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/661Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA957938A 1994-09-22 1995-09-20 Estramustine formulations with improved pharmaceutical properties ZA957938B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9419153A GB9419153D0 (en) 1994-09-22 1994-09-22 Estramustine formulations with improved pharmaceutical properties

Publications (1)

Publication Number Publication Date
ZA957938B true ZA957938B (en) 1996-04-18

Family

ID=10761769

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA957938A ZA957938B (en) 1994-09-22 1995-09-20 Estramustine formulations with improved pharmaceutical properties

Country Status (27)

Country Link
US (1) US5712260A (xx)
EP (1) EP0730474B1 (xx)
JP (1) JP3568957B2 (xx)
KR (1) KR960705587A (xx)
CN (1) CN1135719A (xx)
AT (1) ATE219378T1 (xx)
AU (1) AU698425B2 (xx)
CA (1) CA2174968A1 (xx)
CZ (1) CZ292125B6 (xx)
DE (1) DE69527129T2 (xx)
DK (1) DK0730474T3 (xx)
ES (1) ES2179115T3 (xx)
FI (1) FI962120A0 (xx)
GB (1) GB9419153D0 (xx)
HU (1) HUT75935A (xx)
IL (1) IL115376A (xx)
MX (1) MX9601852A (xx)
MY (1) MY115689A (xx)
NO (1) NO314438B1 (xx)
NZ (1) NZ292895A (xx)
PL (1) PL183132B1 (xx)
PT (1) PT730474E (xx)
RU (1) RU2179036C2 (xx)
TW (1) TW496739B (xx)
UA (1) UA48126C2 (xx)
WO (1) WO1996009072A1 (xx)
ZA (1) ZA957938B (xx)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9921958D0 (en) 1999-09-16 1999-11-17 Pharmacia & Upjohn Spa Formulations for parenteral use of estramustine phosphate and sulfoalkylether-cyclodextrins
GB9921954D0 (en) * 1999-09-16 1999-11-17 Pharmacia & Upjohn Spa Formulations for parenteral use of estramustine phosphate with improved pharmacological properties
ITMI20031015A1 (it) * 2003-05-20 2004-11-21 Naxospharma S R L Poli-(amminopirrolcarbossammidi) per uso nella profilassi e nel trattamento delle endoparassitosi animali e loro composizioni con ciclodestrine.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3299104A (en) * 1963-04-09 1967-01-17 Leo Ab Certain steroid nu-bis-(haloethyl)-carbamates
JPS6327440A (ja) * 1986-07-18 1988-02-05 Sanraku Inc グルコシル化分岐シクロデキストリン含有組成物
SE8802402D0 (sv) * 1988-06-28 1988-06-28 Pharmacia Ab Novel esters
GB8920135D0 (en) * 1989-09-06 1989-10-18 Erba Carlo Spa Use of dehydrated cyclodextrins for improving drug dissolution
FR2667070A1 (fr) * 1990-09-21 1992-03-27 Besins Iscovesco Labo Sterouides inclus dans des cyclodextrines procede pour leur preparation complexes et formes goleniques correspondants et leurs applications therapeutiques.

Also Published As

Publication number Publication date
CZ145696A3 (en) 1996-08-14
FI962120A (fi) 1996-05-20
DK0730474T3 (da) 2002-09-23
NO314438B1 (no) 2003-03-24
JPH09505832A (ja) 1997-06-10
HU9601738D0 (en) 1996-08-28
ES2179115T3 (es) 2003-01-16
HUT75935A (en) 1997-05-28
DE69527129T2 (de) 2003-03-06
PL183132B1 (pl) 2002-05-31
CA2174968A1 (en) 1996-03-28
AU3519995A (en) 1996-04-09
MY115689A (en) 2003-08-30
IL115376A0 (en) 1995-12-31
NO961979L (no) 1996-05-14
IL115376A (en) 1999-05-09
TW496739B (en) 2002-08-01
KR960705587A (ko) 1996-11-08
CN1135719A (zh) 1996-11-13
PL314584A1 (en) 1996-09-16
MX9601852A (es) 1997-03-29
UA48126C2 (uk) 2002-08-15
GB9419153D0 (en) 1994-11-09
NO961979D0 (no) 1996-05-14
ATE219378T1 (de) 2002-07-15
PT730474E (pt) 2002-11-29
AU698425B2 (en) 1998-10-29
WO1996009072A1 (en) 1996-03-28
EP0730474B1 (en) 2002-06-19
RU2179036C2 (ru) 2002-02-10
EP0730474A1 (en) 1996-09-11
FI962120A0 (fi) 1996-05-20
CZ292125B6 (cs) 2003-08-13
NZ292895A (en) 1998-04-27
JP3568957B2 (ja) 2004-09-22
US5712260A (en) 1998-01-27
DE69527129D1 (de) 2002-07-25

Similar Documents

Publication Publication Date Title
AU4264396A (en) Cosmetic or pharmaceutical compositions containing mangiferin or derivatives thereof
AU2003225617A1 (en) Thiadiazolylpiperazine derivatives useful for treating or preventing pain
KR960700708A (ko) 3,4-디아릴크로만을 이용한 뼈 손실의 억제방법(methdos for inhibiting bone loss with 3,4-diarylchroman)
YU13695A (sh) Upotreba 2-fenil-3-aroilbenzotiofena i njihove farmaceutske formulacije
LU91206I2 (fr) Ceftiofur sous forme d'acide libre cristallin et ses dérivés pharmaceutiquement acceptables (naxcel)
CA2302568A1 (en) Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
CA2321547A1 (en) Indole derivatives and medicinal compositions containing the same
HUP0100024A2 (hu) Alzheimer-kór kezelésére szolgáló hatóanyagként karvedilolszármazékokat tartalmazó gyógyszerkészítmények
AU2413895A (en) Amide derivatives and their therapeutic use
ZA922910B (en) Heterocylic pharmaceutical compounds preparation and use
GB9419153D0 (en) Estramustine formulations with improved pharmaceutical properties
HU9600758D0 (en) Diclofenac composition of diminished gastrointestinal irritation and enhanced biological resorption
ZA956476B (en) N-substituted azobiccloheptane derivatives, the preparation and use thereof.
CA2284041A1 (en) Indolecarboxamides, pharmaceutical compositions and methods of inhibiting calpain
ZA935045B (en) Pharmacologically active alfa-(tertiary-aminomethyl)-ben-zenemethanol derivatives
HUP0203045A2 (hu) Epesavval képezett 4-benzil-amino-kinolin konjugátumok és hetero-analógjai, valamint eljárás a vegyületek előállítására és a vegyületeket tartalmazó gyógyászati készítmények, és ezek alkalmazása
RU97113692A (ru) Применение 3,4-дифенилхроманов для получения фармацевтической композиции для лечения или профилактики церебральных дегенеративных расстройств
IT1252169B (it) Composizioni terapeutiche adatte per la somministrazione orale contenenti come principio attivo uno o piu' tioesteri del glutatione, e procedimento per la preparazione dei suddetti principi attivi
RU97113700A (ru) Применение 3,4-дифенилхроманов для получения фармацевтической композиции для лечения или профилактики ожирения
RU98114985A (ru) Применение 3,4-дифенилхроманов для производства фармацевтического состава для лечения или профилактики симптомов менопаузы